Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Navidea Biopharmaceuticals Inc's Business Segments
Navidea Biopharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q3 FY2022
Reportable Segments
1
Largest Segment
Diagnostics Segment
Total Revenue
$ 0
Regions Reported
-
Revenue Share by Reportable Segment - Q3 FY2022
- Diagnostics Segment0%
Revenue by Reportable Segment - Q3 FY2022
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Diagnostics Segment | $ 0 | - |
Revenue by Product & Service Category - Q3 FY2022
- Sales Revenue0%
- Grant0%
Revenue by Product & Service Category - Q3 FY2022
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Sales Revenue | $ 0 | - |
| Grant | - | 0% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Navidea Biopharmaceuticals Inc
Navidea Biopharmaceuticals Inc is a biopharmaceutical company headquartered in Dublin, Ohio. The company primarily focuses on the development of precision immunodiagnostic agents and immunotherapy platforms. It was founded in 1983 as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals in 2012.
Navidea Biopharmaceuticals specializes in precision radiopharmaceuticals, which are used to improve patient care and clinical outcomes in the field of nuclear medicine. These radiopharmaceuticals are designed to selectively target specific molecules or receptors on diseased cells, allowing for more accurate diagnosis and targeted treatment.
The company's product portfolio includes several precision radiopharmaceuticals under various stages of development. Its leading product candidate is Lymphoseek, an innovative sentinel lymph node mapping agent indicated for the detection of lymph nodes that may contain cancer cells in patients with breast cancer, melanoma, and other solid tumors. Lymphoseek has gained regulatory approval in the United States and European Union and is marketed and distributed by the company's commercial partner.
In addition to Lymphoseek, Navidea Biopharmaceuticals is actively developing other precision radiopharmaceuticals. These include agents for imaging and characterizing neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease, as well as agents for the detection and staging of various cancers, including ovarian cancer, colorectal cancer, and prostate cancer.
Navidea Biopharmaceuticals has established collaborations with leading academic institutions, research organizations, and pharmaceutical companies to advance its product pipeline. These collaborations enable the company to leverage expertise and resources to accelerate the development and commercialization of its precision radiopharmaceuticals.
Apart from its radiopharmaceutical programs, Navidea Biopharmaceuticals is also involved in the development of immunotherapy platforms. It is developing proprietary technology platforms, including Tc99m tilmanocept and Manocept, which have the potential to deliver diagnostics and therapeutics to immune cells. These platforms aim to enhance the body's immune response against cancer and other diseases.
The company actively engages in research and development activities, leveraging its expertise in precision medicine, molecular imaging, and immunotherapy. It has a team of scientists, clinicians, and industry experts who collaborate to advance the understanding and treatment of various diseases.
Navidea Biopharmaceuticals has a strong intellectual property portfolio, with a number of patents and patent applications covering its technology platforms and product candidates. This provides the company with competitive advantages and opportunities for licensing and partnership agreements.
In summary, Navidea Biopharmaceuticals Inc is a biopharmaceutical company that specializes in precision radiopharmaceuticals and immunotherapy platforms. With a focus on precision medicine, the company aims to improve patient care and clinical outcomes in the field of nuclear medicine. Its product pipeline includes innovative diagnostic agents and therapies for the detection and treatment of cancer and neurodegenerative diseases. With collaborations and a strong intellectual property portfolio, Navidea Biopharmaceuticals is poised to make significant contributions to the field of precision medicine.
Navidea Biopharmaceuticals specializes in precision radiopharmaceuticals, which are used to improve patient care and clinical outcomes in the field of nuclear medicine. These radiopharmaceuticals are designed to selectively target specific molecules or receptors on diseased cells, allowing for more accurate diagnosis and targeted treatment.
The company's product portfolio includes several precision radiopharmaceuticals under various stages of development. Its leading product candidate is Lymphoseek, an innovative sentinel lymph node mapping agent indicated for the detection of lymph nodes that may contain cancer cells in patients with breast cancer, melanoma, and other solid tumors. Lymphoseek has gained regulatory approval in the United States and European Union and is marketed and distributed by the company's commercial partner.
In addition to Lymphoseek, Navidea Biopharmaceuticals is actively developing other precision radiopharmaceuticals. These include agents for imaging and characterizing neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease, as well as agents for the detection and staging of various cancers, including ovarian cancer, colorectal cancer, and prostate cancer.
Navidea Biopharmaceuticals has established collaborations with leading academic institutions, research organizations, and pharmaceutical companies to advance its product pipeline. These collaborations enable the company to leverage expertise and resources to accelerate the development and commercialization of its precision radiopharmaceuticals.
Apart from its radiopharmaceutical programs, Navidea Biopharmaceuticals is also involved in the development of immunotherapy platforms. It is developing proprietary technology platforms, including Tc99m tilmanocept and Manocept, which have the potential to deliver diagnostics and therapeutics to immune cells. These platforms aim to enhance the body's immune response against cancer and other diseases.
The company actively engages in research and development activities, leveraging its expertise in precision medicine, molecular imaging, and immunotherapy. It has a team of scientists, clinicians, and industry experts who collaborate to advance the understanding and treatment of various diseases.
Navidea Biopharmaceuticals has a strong intellectual property portfolio, with a number of patents and patent applications covering its technology platforms and product candidates. This provides the company with competitive advantages and opportunities for licensing and partnership agreements.
In summary, Navidea Biopharmaceuticals Inc is a biopharmaceutical company that specializes in precision radiopharmaceuticals and immunotherapy platforms. With a focus on precision medicine, the company aims to improve patient care and clinical outcomes in the field of nuclear medicine. Its product pipeline includes innovative diagnostic agents and therapies for the detection and treatment of cancer and neurodegenerative diseases. With collaborations and a strong intellectual property portfolio, Navidea Biopharmaceuticals is poised to make significant contributions to the field of precision medicine.
Navidea Biopharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of innovative imaging agents and therapeutic products aimed at improving patient care, particularly in the fields of oncology, neurological diseases, and inflammatory disorders. Here is an extensive overview of their segments, products, and services:
Segments
1. Imaging Agents:
- Navidea specializes in the development of precision imaging agents that utilize nuclear medicine and molecular imaging techniques. These imaging agents enable healthcare professionals to visualize and assess various diseases more effectively.
2. Therapeutic Development:
- Alongside their imaging solutions, Navidea is engaged in the development of therapeutic compounds, often targeting pathways associated with diseases visible through their imaging technologies.
3. Clinical and Preclinical Services:
- The company provides a platform to support the clinical evaluation of its imaging and therapeutic products. They may engage in partnerships with research institutions and other biopharmaceutical companies to advance their pipeline.
4. Collaborations and Partnerships:
- Navidea often collaborates with other biopharmaceutical firms, research entities, and academic institutions to harness synergies in product development and broadening the application of their technologies.
Products
1. Lymphoseek:
- This is Navideas flagship product, a radiopharmaceutical agent specifically designed for sentinel lymph node detection in cancer patients. It is used during surgical procedures to help identify lymph nodes that may contain cancer, thereby assisting in more accurate staging of the disease and informing treatment strategies.
2. NAV4694:
- An imaging agent aimed at aiding in the diagnosis of Alzheimer’s disease by binding to β-amyloid plaques in the brain. It is in various stages of clinical evaluation and represents a significant advancement in the imaging of neurological disorders.
3. NAV5001:
- This imaging agent is designed for use in the diagnosis of Parkinsonian syndromes, providing a means to visualize and quantify dopamine transporter levels in the brain. This can help differentiate between Parkinson’s disease and other conditions with similar symptoms.
4. Therapeutic Candidates:
- Navidea is also involved in the development of therapeutic agents, particularly those targeting autoimmune and inflammatory diseases, leveraging their expertise in immune system modulation and the role of macrophages in disease pathways.
Services
1. Clinical Trials:
- Navidea conducts clinical trials to evaluate the safety and efficacy of its products. They manage these trials according to regulatory standards and work closely with clinical researchers to gather data that supports their product claims.
2. Regulatory Services:
- The company navigates the complexities of regulatory approval processes for both imaging and therapeutic products. This includes interactions with regulatory bodies like the FDA and EMA, submission of Investigational New Drug (IND) applications, and support for market approval.
3. Research and Development:
- Navidea invests heavily in R&D to enhance their product offerings continually. This includes improving existing products, exploring new indications for current products, and developing new agents that leverage their imaging and therapeutic expertise.
4. Partnership and Licensing Opportunities:
- The company seeks collaborations with other pharmaceutical companies to expand its research capabilities and market reach. This may involve licensing its technologies or entering joint development agreements to utilize its products in broader applications.
5. Educational Programs:
- Navidea may also engage in educational initiatives aimed at informing healthcare professionals about the latest advances in imaging diagnostics and treatment approaches, fostering better clinical practices.
Conclusion
Navidea Biopharmaceuticals Inc. stands as a key player in the field of biopharmaceuticals, particularly through its innovative imaging technologies and therapeutic developments. Their focus on precision medicine, cross-disciplinary collaborations, and commitment to advancing diagnostic and therapeutic options positions them as a significant entity in the biopharmaceutical landscape.
Segments
1. Imaging Agents:
- Navidea specializes in the development of precision imaging agents that utilize nuclear medicine and molecular imaging techniques. These imaging agents enable healthcare professionals to visualize and assess various diseases more effectively.
2. Therapeutic Development:
- Alongside their imaging solutions, Navidea is engaged in the development of therapeutic compounds, often targeting pathways associated with diseases visible through their imaging technologies.
3. Clinical and Preclinical Services:
- The company provides a platform to support the clinical evaluation of its imaging and therapeutic products. They may engage in partnerships with research institutions and other biopharmaceutical companies to advance their pipeline.
4. Collaborations and Partnerships:
- Navidea often collaborates with other biopharmaceutical firms, research entities, and academic institutions to harness synergies in product development and broadening the application of their technologies.
Products
1. Lymphoseek:
- This is Navideas flagship product, a radiopharmaceutical agent specifically designed for sentinel lymph node detection in cancer patients. It is used during surgical procedures to help identify lymph nodes that may contain cancer, thereby assisting in more accurate staging of the disease and informing treatment strategies.
2. NAV4694:
- An imaging agent aimed at aiding in the diagnosis of Alzheimer’s disease by binding to β-amyloid plaques in the brain. It is in various stages of clinical evaluation and represents a significant advancement in the imaging of neurological disorders.
3. NAV5001:
- This imaging agent is designed for use in the diagnosis of Parkinsonian syndromes, providing a means to visualize and quantify dopamine transporter levels in the brain. This can help differentiate between Parkinson’s disease and other conditions with similar symptoms.
4. Therapeutic Candidates:
- Navidea is also involved in the development of therapeutic agents, particularly those targeting autoimmune and inflammatory diseases, leveraging their expertise in immune system modulation and the role of macrophages in disease pathways.
Services
1. Clinical Trials:
- Navidea conducts clinical trials to evaluate the safety and efficacy of its products. They manage these trials according to regulatory standards and work closely with clinical researchers to gather data that supports their product claims.
2. Regulatory Services:
- The company navigates the complexities of regulatory approval processes for both imaging and therapeutic products. This includes interactions with regulatory bodies like the FDA and EMA, submission of Investigational New Drug (IND) applications, and support for market approval.
3. Research and Development:
- Navidea invests heavily in R&D to enhance their product offerings continually. This includes improving existing products, exploring new indications for current products, and developing new agents that leverage their imaging and therapeutic expertise.
4. Partnership and Licensing Opportunities:
- The company seeks collaborations with other pharmaceutical companies to expand its research capabilities and market reach. This may involve licensing its technologies or entering joint development agreements to utilize its products in broader applications.
5. Educational Programs:
- Navidea may also engage in educational initiatives aimed at informing healthcare professionals about the latest advances in imaging diagnostics and treatment approaches, fostering better clinical practices.
Conclusion
Navidea Biopharmaceuticals Inc. stands as a key player in the field of biopharmaceuticals, particularly through its innovative imaging technologies and therapeutic developments. Their focus on precision medicine, cross-disciplinary collaborations, and commitment to advancing diagnostic and therapeutic options positions them as a significant entity in the biopharmaceutical landscape.